# Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin

> **NCT01163851** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 25 (actual)

## Conditions studied

- Hypercholesterolemia
- Dyslipidemia

## Interventions

- **BIOLOGICAL:** 4 mg/kg
- **BIOLOGICAL:** 0.5 mg/kg

## Key facts

- **NCT ID:** NCT01163851
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2011-02
- **Final completion:** 2011-04
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01163851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01163851, "Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01163851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*